A study announced at the Union World Conference today has reported that 80 percent of participants on the trial were cured of drug-resistant tuberculosis (DR-TB) thanks to a new treatment.
The cohort study in Belarus analysed the use of bedaquiline to treat patients with multi- and extensively drug-resistant TB.
Out of the 181 participants, the final results showed 93 percent had treatment success (168) and 144 participants were cured (80 percent). These are excellent outcomes given the proportion of participants with extensively drug-resistant TB.
Paula Fujiwara, Scientific Director of The Union: “The results from this study confirm that newer drugs like bedaquiline can cure and are game changers for people living with multidrug-resistant and extremely drug-resistant tuberculosis.”
Bedaquiline containing regimens in the treatment of multi- and extensively drug-resistant tuberculosis at the programmatic level. Prospective cohort study will be presented at the ‘Innovative treatment for MDR-TB’ session, in Amazon, on Friday at 16:00-17:30.